Context: Subclinical hypothyroidism (SCH) is associated with cardiovascular (CV) risk factors, and possibly CV disease. However, its management remains controversial. Endothelial progenitor cells (EPC), expressing both endothelial and stem cell markers, are known to offer a novel CV risk marker.
Objective: The aim of the study was to ascertain whether EPC count or function is reduced in SCH and whether it improves with T(4) therapy.
Design And Intervention: EPC were studied in peripheral blood by fluorescence-activated cell sorter and following in vitro cultures before and after T(4) together with CV risk factors in 20 SCH and healthy controls (HC).
Main Outcome Measure: EPC count was measured at baseline and after T(4) replacement in SCH.
Results: EPC count was significantly reduced in SCH compared to HC: median (range)-CD133+/VEGFR-2+, 0.09 (0.02-0.44) vs. 0.47 (0.17-2.12), P < 0.001; CD34+/VEGFR-2+, 0.10 (0.04-0.46) vs. 0.39 (0.11-2.13), P < 0.001; whereas EPC function was similar. There was a significant positive correlation between CD133+/VEGFR-2+ with free T(4) levels (r = 0.38; P = 0.02); high-density lipoprotein cholesterol levels (r = 0.51; P = 0.001); and negative correlation with TSH concentrations (r = -0.64; P < 0.001). After adjustment for conventional CV risk factors, SCH predicted lower EPC count, beta coefficient/P value: CD133+/VEGFR-2+ (-0.77/<0.001), and CD34+/VEGFR-2+ (-0.71/<0.001). In SCH participants, EPC count increased and was similar to HC after T(4); CD133+/VEGFR-2+, 0.32 (0.03-0.94) vs. 0.09 (0.02-0.44), P < 0.001; and CD34+/VEGFR-2+, 0.26 (0.06-0.88) vs. 0.10 (0.04-0.46), P < 0.001.
Conclusion: SCH predicted lower EPC count, which improved with T(4) treatment, independent of other CV risk factors, providing additional evidence that T(4) replacement may improve CV risk in SCH.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1210/jc.2009-1421 | DOI Listing |
J Caring Sci
October 2024
School of Nursing & Health Studies, University of Missouri-Kansas City, Kansas City, MO, United States.
Introduction: : Healthcare advances have contributed to patients living longer with chronic illnesses and diseases with uncertain trajectories impacting quality of life (QOL). Palliative care (PC) is no longer only for dying oncology patients as many healthcare practitioners have adopted the PC concept in diverse care settings and the timing of PC implementation remains ambiguous. There is a need to develop an operational definition of early palliative care (EPC) by clarifying the phenomenon and bridging concepts with empirical data to develop and test possible interventions before integrating EPC into emergency care (EC).
View Article and Find Full Text PDFArch Virol
November 2024
Chinese Academy of Inspection and Quarantine, Beijing, 100176, China.
Stem Cell Rev Rep
November 2024
Academic Stroke, Mental Health & Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, NG7 2UH, UK.
Endothelial progenitor cells (EPCs) are stem cells that can repair injured blood vessels through neovascularisation. This is achieved through secretion of growth factors and endothelial maturation. EPC numbers and function have been studied to determine their diagnostic, prognostic and therapeutic potential in many ischaemic diseases such as stroke.
View Article and Find Full Text PDFAm J Transl Res
June 2024
Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Guangxi Medical University Nanning 530000, Guangxi, P. R. China.
Objectives: Endothelial progenitor cells (EPCs) play a crucial role in acquired angiogenesis and endothelial injury repair. Transient receptor potential canonical channel 4 (TRPC4), a key component of store-operated calcium channels, is essential for EPC function. While the role of TRPCs has been clarified in vascular diseases, the relationship between TRPC4 and EPC function, along with the underlying molecular mechanisms, remains unclear and requires further elucidation.
View Article and Find Full Text PDFPediatr Blood Cancer
July 2024
Division of Pulmonary Biology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center & University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Background: Angiopoietin-2 (Ang-2) is increased in the blood of patients with kaposiform lymphangiomatosis (KLA) and kaposiform hemangioendothelioma (KHE). While the genetic causes of KHE are not clear, a somatic activating NRAS mutation has been found in the lesions of KLA patients.
Procedure: Our study tested the hypothesis that the NRAS mutation drives elevated Ang-2 expression in endothelial cells.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!